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INTRODUCTION
The first descriptions of ocular inflammation date back to 1500 
BC (Ebers’s papyrus) (1). The term uveitis was first used to characterize 
any type of intraocular inflammation with non-infectious etiology. 
Au toimmune uveitis is a constant challenge for researchers due to 
its variable clinical presentation, evolution, recurrence rates, and etio -
logy, which is still not completely understood.
Uveitis is classified as autoimmune according to clinical criteria(2). 
Basically, non-infectious intraocular inflammation that presents good 
response to anti-inflammatory drugs is classified as autoimmune. In 
some cases, an association with major histocompatibility complex 
(MHC) molecules can be found.
In order to understand the pathophysiology of autoimmune uvei tis 
and develop new therapies, it is important to identify the pos sible 
antigens involved in the disease. The use of experimental models is 
important as there are many difficulties involved in getting intraocu-
lar tissue from patients’ eyes, including technical and ethical issues. 
Experimental models are important for the development of new the-
rapeutic agents as they are useful to evaluate the efficacy and toxicity 
of systemic and intravitreous drug delivery, such as antibiotics(3-5), 
corticosteroids(6,7), immunosuppressive drugs(8,9), and more recently 
anti-VEGF(10,11), and biological agents (e.g., tacrolimus, sirolimus, eta-
nercept, infliximab, adalimumab, and rituximab)(12-19).
The aim of this paper is to review the most used experimental 
autoimmune ocular inflammatory diseases models used in Ophthal-
mology and their most important aspects.
MODels Of aUTOIMMUNe OCUlaR DIsease aND  
OCUlaR INflaMMaTION
In the past 50 years, several experimental models of non-infec-
tious ocular inflammation have been described(20-25). Different parts 
of the eye of the animal model can become inflamed, simulating the 
different types of uveitis humans. The most used model is the expe-
rimental autoimmune uveitis (EAU). Inflammation can be induced 
by retinal antigens, such as S-antigen and the interphotoreceptor 
retinoid-binding protein (IRBP), but other non-retinal antigens and 
non-ocular antigens can also be used, as bacterial endotoxin and 
cytokines.
Animal models are very heterogeneous in terms of inflammatory 
response. Even animals of the same species do not respond the same 
way to the same antigen, so the information obtained from each of 
Experimental models of autoimmune inflammatory ocular diseases
Modelos experimentais para o estudo de doenças inflamatórias oculares autoimunes
Fabio Gasparin1, beatriz sayuri takahashi1, Mariana raMos scolari2, Filipe Gasparin3, lycia saMpaio pedral4, Francisco Max daMico1
 Submitted for publication: January 2, 2012
 Accepted for publication: January 26, 2012
 Study carried out at Department of Ophthalmology, Hospital das Clínicas da Faculdade de Medicina 
da Universidade de São Paulo.
1 Physician, Universidade de São Paulo - USP, São Paulo (SP), Brazil.
2 Medical student, Universidade de São Paulo - USP - São Paulo (SP), Brazil.
3 Physician, Department of Ophthalmology, Universidade Estadual Paulista “Júlio de Mesquita 
Filho” - UNESP - Botucatu (SP), Brazil.
4 Medical student, Escola Bahiana de Medicina e Saúde Pública, Salvador (BA), Brazil.
 Funding: No specific financial support was available for this study.
 Disclosure of potential conflicts of interest: F.Gasparin, None; B.S.Takahashi, None; M.R.Scolari, 
None; F.Gasparin, None; L.S.Pedral, None; F.M.Damico, None.
 Correspondence address: Fabio Gasparin. Av. Princesa Izabel, 274 - apto. 201 - Uberlândia - MG 
- 38400-192 - Brazil - E-mail: fgasparin@usp.br
aBsTRaCT
Ocular inflammation is one of the leading causes of blindness and loss of vision. 
Human uveitis is a complex and heterogeneous group of diseases characterized 
by inflammation of intraocular tissues. The eye may be the only organ involved, 
or uveitis may be part of a systemic disease. A significant number of cases are of 
unknown etiology and are labeled idiopathic. Animal models have been developed 
to the study of the physiopathogenesis of autoimmune uveitis due to the difficulty 
in obtaining human eye inflamed tissues for experiments. Most of those models are 
induced by injection of specific photoreceptors proteins (e.g., S-antigen, interpho-
toreceptor retinoid-binding protein, rhodopsin, recoverin, phosducin). Non-retinal 
antigens, including melanin-associated proteins and myelin basic protein, are also 
good inducers of uveitis in animals. Understanding the basic mechanisms and 
pathogenesis of autoimmune ocular diseases are essential for the development of 
new treatment approaches and therapeutic agents. The present review describes 
the main experimental models of autoimmune ocular inflammatory diseases.
Keywords: Animal models; Uveitis/etiology; Autoimmune diseases; Inflammation
RESUMO
A inflamação ocular é uma das principais causas de perda visual e cegueira. As uveítes 
constituem um grupo complexo e heterogêneo de doenças caracterizadas por infla-
mação dos tecidos intraoculares. O olho pode ser o único órgão envolvido ou a uveíte 
pode ser parte de uma doença sistêmica. A etiologia é desconhecida em um número 
significativo de casos, que são considerados idiopáticos. Modelos animais têm sido 
desenvolvidos para estudar a fisiopatogênese da uveíte autoimune devido às dificul-
dades na obtenção de tecidos de olhos humanos inflamados para experimentos. Na 
maioria desses modelos, que simulam as uveítes autoimunes em humanos, a uveíte é 
induzida com proteínas específicas de fotorreceptores (antígeno-S, proteína ligadora 
de retinoide do interfotoreceptor, rodopsina, recoverina e fosducina). Antígenos não 
retinianos, como proteínas associadas à melanina e proteína básica de mielina, são 
também bons indutores de uveíte em animais. Entender os mecanismos básicos e a 
patogênese dessas doenças oculares é essencial para o desenvolvimento de novas 
formas de tratamento das uveítes autoimunes e de novos agentes terapêuticos. Nesta 
revisão serão abordados os principais modelos experimentais utilizados para o estudo 
de doenças inflamatórias oculares autoimunes.
Descritores: Modelos animais; Uveítes/etiologia; Doenças autoimunes; Inflamação
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the available models are complementary(25). Table 1 shows the most 
used models for the study of autoimmune ocular inflammatory 
diseases.
1. ExpErimEntal autoimmunE uvEitis (Eau)
EAU is the most used model for the study of autoimmune ocular 
inflammation, especially in the posterior segment. It is induced by 
the subcutaneous injection of a single dose of soluble retinal anti-
gen(21,26). The EAU clinical and pathological characteristics depend on 
the species and the antigen used for induction, but T-cell mediated 
inflammatory response is always present, mainly CD4+ cells. CD4+ 
cells recognize antigens presented by antigen presenting cells (APC) 
in the context of class II main histocompatibility complex (MHC) 
molecules. Pro-inflammatory cytokines, such as IL-2, IFN-g, and TNF-α 
are produced by the subset Th1 and are important mediators of the 
cellular immune response(27).
1.1 S-Antigen
The S-antigen, also called S-arrestin, is a photoreceptor protein 
present in abundance in photoreceptors and pineal gland cells(21). 
It plays a physiological role in desensitization of the photoactivated 
transduction cascade by inhibiting coupling of rhodopsin to trans -
ducin. In addition, S-antigen is highly antigenic and is a potent indu-
cer of autoimmune uveoretinitis in animals.
EAU is induced by the subcutaneous injection of bovine S-anti-
gen along with the complete Freund’s adjuvant (CFA) as vehicle(28). 
The inflammatory response begins between 10 days and 2 months 
and lasts from few days to 1 year, depending on the species and the 
dose of the antigen. In Lewis rats, the inflammation is acute and self-
li mited but it causes important damage to the retina and choroid 
within few days(29). The disease is less severe and subacute in other 
rat strains, guinea pigs, and monkeys. In the latter, the di sease may 
present a longer course with progressive destruction of the retina(29).
Each antigen has a group of antigenic determinants called epito-
pes. Epitopes are sequences of amino acids that elicit inflammatory 
response after recognition by the immune system. Some antigens 
may present various different epitopes, or the same epitopes may 
be present more than once in the same protein. Peptide M is an 
18-amino acid component of S-antigen that has been shown to be 
highly uveitopathogenic in different species, such as rats, guinea pigs, 
and monkeys, producing inflammatory changes in eyes very similar 
to those induced by native S-antigen(30). In humans, the amino acids 
sequence of the S-antigen corresponding to peptide M was found to 
be virtually identical to that of the bovine S-antigen(31).
Immunological mimicry between host and microbial proteins has 
been suggested as a potential mechanism in the development of uvei-
tis in humans. Cross-reactivity between anti-streptococcal monoclo-
nal antibodies with retinal S-antigen from rods of the human eye 
hu man eye has been demonstrated, suggesting that both molecules 
share epitopes of antigenic similarity. These findings may suggest a 
possible association between host and microbial proteins, which may 
be a potential mechanism in the development of human uveitis(32).
1.2 Interphotoreceptor retinoid-binding protein
IRBP is a protein found primarily between the retinal pigment 
epi thelium (RPE) and the photoreceptor cells. It plays a role in the 
trans port of the retinoids, a product of vitamin A, between the retina 
and the RPE cells(33,34). Uveitis is induced by subcutaneous injection 
of isolated bovine IRPB or part of bovine IRPB associated to per tussis 
toxin with CFA as vehicle(35). IRBP is a strong uveitis inducer in rats(36), 
monkeys(37), rabbits(38), and mice(22). However, it is a weak inducer in 
guinea pigs(39). The clinical course and severity of EAU depend on the 
antigen dosage, the animal species, and the association of pertussis 
toxin at the moment of induction. In Lewis rats, the acute inflamma-
tion may be severe and begin from 8 to 12 days after immunization, 
lasting 5 to 10 days(36). In mice, uveitis has longer incubation and lasts 
longer. Mild anterior uveitis may be present and the prominent retinal 
findings are vasculitis, granuloma, serous detachment, and loss of 
photoreceptors. Other findings include sub-RPE infiltrates (clinical 
equivalent of Dallen-Fuchs nodules) and thickening of the choroid 
and ciliary body(40).
IRBP molecule has 1,264 amino acids, forming 4 repeated units 
of 300 amino acids each. Each unit presents an uveitogenic site. The 
peptide 1117-1191 of bovine IRBP is capable of generating important 
uveal inflammation(41,42). Another study suggests that the rat IRBP 
peptide 273-283 also elicits severe uveitis(43). Approximately 84% of 
the bovine and human IRBP present identical sequence of amino 
acids(44,45). Many studies using EAU models induced by IRBP have 
aimed the identification of the exact immunogenic epitopes(46-48) 
and interactions with the MHC molecules. Specific IRBP epitopes 
ha ve already been recognized as uveitogenic in susceptible mice 
strains: Peptide 1-20 for C57BL/6, 161-180 for B10.RIII, and 201-216 
for B10.A(49), and recent studies revealed several additional uveito-
genic epitopes of human IRBP molecule that elicit EAU in mice(48).
2. ExpErimEntal mElanin protEin-inducEd uvEitis (Emiu)
Non-soluble melanin proteins isolated from pigmented bovine 
eye tissues can induce an uveitis model named EMIU(50,51). According 
to Matteson et al.(52), this model can be induced by subcutaneous 
injection of melanin proteins in association with Hunter adjuvant.
CD4+ T cells are the primary mediators of the inflammatory res -
ponse, as well as in EAU(53), but the target tissue is the uvea, where 
the melanocytes are located, not the retina. Therefore, ocular inflam-
mation is mostly evident in the iris, ciliary body, and choroid. Clinical 
manifestations begin 10 to 14 days after induction and consists of 
con junctival hyperemia, corneal edema, anterior uveitis, iris vessels 
dilation, hypopyon, and synechiae(40). The 2-week acute uveitis may 
present spontaneous recurrences as observed in EAU in mice(54).
Table 1. Comparison among animal models for the study of autoimmune uveitis
Model antigen Target Clinical relevance
Experimental autoimmune uveitis (EAU) S-Antigen
IRBP
Rodpsin
Recoverin
Phosducin
Photoreceptors Posterior uveitis
Experimental melanin protein-induced 
uveitis (EMIU)
Melanin protein Uveal melanocytes Anterior uveitis
Posterior uveitis
Difuse uveitis
Encephalitis associated uveitis (EAE/AU) Mielin binding protein Iris myelinated nerves 
and spinal cord
Anterior uveitis
Multiple sclerosis
Gasparin F, et al.
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Histologically, ocular inflammation is characterized by the pre-
sence of macrophages and lymphocytes. Except on severe and 
re current cases, the RPE, retina, and optic nerve are rarely involved, 
even though they can be affected when low dose endotoxins are 
added(55).
IL-2 and IFN-γ are the predominant intraocular cytokines produ -
ced early in the disease, then IL-12, and finally TNF-α at the peak of 
the inflammation. Other inflammatory mediators such as nitric oxide 
are also involved in the inflammatory response(40,52).
Yamaki et al. described the induction of uveoretinitis in rats by 
peptides derived from tyrosinase, a melanocyte differentiation pro-
tein(56,57). After immunization, animals develop uveitis, cutaneous 
vi tiligo, and meningitis, a disease similar to Vogt-Koyanagi-Harada 
(VKH) disease in humans. Damico et al. have shown the importance 
of peptides derived from human melanocyte differentiation pro -
teins on the pathogenesis of VKH disease in humans, reinforcing the 
important role of melanin proteins in the pathogenesis of certain 
autoimmune uveitis(58).
3. ExpErimEntal autoimmunE EncEphalitis associatEd to  
antErior uvEitis (EaE/au)
This experimental model is characterized by relapsing anterior 
uveitis associated to encephalitis. Myelin basic protein (MBP) induces 
inflammation in rats eyes after subcutaneous injection associated to 
CFA(59).
MBP is highly expressed in the peripheral nervous fibers and in 
the central nervous system. This protein is produced by myelinated 
cells from the iris nerves and oligodendrocytes, and these cells may 
be the target of the autoantigens in multiple sclerosis associated 
uveitis(40).
Ten to 12 days after immunization, eyes present with iris vessel 
dilation, anterior uveitis, hypopyon, and synechia, which persist for 
about 30 days(60). Inflammation severity depends on the species 
sus ceptibility, myelin quantity in each animal, and MBP dose(25). If 
severe, the inflammation affects the posterior segment, with optic 
nerve inflammation. Encephalitis and uveitis usually begin at the 
same time, but uveitis has longer duration and uveitis is still on-
going even after the encephalitis resolves(61,62). IL-2 and IFN-g pro-
duced by Th1 cells are the major inflammatory mediators present 
in this animal model.
Even though the mechanisms for anterior uveitis relapses are not 
well known, studies suggest that MBP minor epitopes are involved 
in the relapses by expansion of the sensitized T cells(63). In Lewis rats, 
inflammatory recurrences are related to some specific MBP epitopes, 
specifically peptides 100-120, 121-141, and 142-67(64). This relapsing 
anterior uveitis model is especially important for the study of some 
types of auto-immune uveitis in humans, which are usually recurrent 
in nature.
4. non-ocular antigEn mEdiatEd uvEitis 
Some experimental uveitis models can be induced by non-ocular 
antigens, mainly bacterial endotoxins. Endotoxin-induced uveitis (EIU) 
can be induced by intravenous, intraperitoneal, or subcutaneous in-
jection of low doses of endotoxins, such as E. coli lipopolysaccharide 
(LPS)(64). LPS is an important component of the outer membrane of 
Gram-negative bacteria, contributing to the structural integrity and 
helping to stabilize its membrane structure. LPS induces a severe im-
mune response in animals.
In the rats, ocular inflammatory signs appear few hours after LPS 
injection and may spontaneously resolve within few days. Repeated 
injections of LPS seem to result in a state of tolerance and the animals 
no longer develop uveitis(65).
Anterior uveitis in Lewis rats can also be induced only by the in -
jection of CFA in around 22% of cases. When Mycobacterium butyricum 
is added, the uveitis incidence rises to 50% or more(66).
The intraocular injections of some cytokines, such as IL-1, IL-6, 
IL-8, and TNF-α, can also be used to induce uveitis in experimental 
models(67,68). New discoveries on the role of cytokines in ocular inflam-
mation, as well as clinical results of cytokine-blocking agents, have 
been made using transgenic animals, which can overexpress or do 
not express the citokines genes. 
5. nEw modEls of ExpErimEntal autoimmunE uvEitis
A particular EAU model can be induced in transgenic mice. These 
animals do not express MHC molecules. Instead, they present the hu-
man HLA class II molecules HLA-DR3, -DR4, -DQ6, or -DQ8(69). As with 
the parental strain C57BL/10, these transgenic mice develop uveitis 
when immunized with IRBP. However, unlike the parental strain, they 
also develop uveitis when in contact with S-antigen(70). This humani-
zed EAU model supports the notion that responses to S-antigen drive 
uveitis in humans and may help to identify additional uveitogenic 
peptides presented by specific HLA molecules(49).
Transgenic mice that express two human HLA alleles, such as DR3 
and DQ6, have been shown to be more susceptible than mice that 
express only one allele. This suggests that there are complementing 
influences between different HLA molecules, and it is possible that 
some alleles combinations may play a protective role(49).
Another model of EAU can be induced by IRBP peptides asso-
ciated to dendritic cells (DC). Dendritic cells are APCs and probably 
the main ones capable of stimulating immature T cells(49). This model 
can be induced by the infusion of DC, matured in vitro with LPS and 
anti-CD40, and pulsed with IRBP peptide 161-180(71). This EAU model 
differs in immunological, clinical, and pathological characteristics 
from the traditional IRBP-CFA model, in which the disease is shorter 
and less severe. The fundus lesions are punctates and there are more 
neutrophils than monocytes(48). This autoimmune uveitis model de -
monstrates that the same antigen may induce different forms of 
uveitis, depending on how they are presented to the immune system, 
and may help to explain the heterogeneity of human uveitis(48).
CONClUsION
Researches on experimental models have been important to 
explain the pathophysiological mechanisms involved in different 
ocular autoimmune inflammatory diseases. EAU is one of the most 
used animal models. After immunization with uveitogenic antigens, 
animals develop an immune response mediated primarily by CD4+ 
T cells. Clinical findings are somewhat similar to some human au-
toimmune uveitis. Even though these models contribute for a better 
understanding of the pathophysiology of autoimmune uveitis in 
humans, there are still many questions to be answered, such as 
triggers, recurrences, and individual susceptibility. Heterogeneous 
clinical findings may be related to the observation that each subject 
may respond to more than one epitope per antigen and respond 
differently to each one of them, depending on how it is presented 
and how it is recognized by the immune system.
Lately, new ocular inflammatory experimental models have been 
available due to the advances in genetics and molecular engineering. 
These models may help the development of news therapies, with 
more specific and efficient drugs, avoiding side effects. In addition, 
animal models are important for the study of new routes of drug 
delivery, especially by intravitreal injection.
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